Acidophil cells of the anterior pituitary are chromophilic cells whose cytoplasm stains with acidic dyes. The category is dominated by somatotrophs, which secrete growth hormone, and lactotrophs, which secrete prolactin. Together they account for roughly half of the hormone-producing cells of the gland, and their number, granule morphology and secretory activity change with age, sex, pregnancy and endocrine state.
Acidophils occupy the pars distalis of the adenohypophysis, the part of the pituitary that forms about four fifths of the gland by weight. The pars distalis is built from nests and cords of epithelial cells separated by sinusoidal capillaries, and acidophils are arranged along these vessels so that secreted peptides enter the portal blood quickly. The pars nervosa and pars intermedia contain no acidophils, and the pars tuberalis contains only scattered cells. Somatotrophs are concentrated in the lateral wings of the pars distalis, whereas lactotrophs are more numerous in the posteromedial region, although the two populations intermingle and cannot be separated reliably by position alone.
On haematoxylin and eosin sections the cytoplasm is uniformly pink to bright red because it is packed with protein-rich secretory granules and rough endoplasmic reticulum. Orange G, azocarmine and modified trichrome stains colour somatotroph and lactotroph granules orange or red, while corticotrophs, thyrotrophs and gonadotrophs contain glycoprotein hormones, stain basophilic and are periodic acid-Schiff positive. Chromophobes are lightly stained cells that are usually degranulated acidophils or basophils rather than a separate functional class. Tinctorial classification therefore suggests a lineage but cannot establish cell identity, which requires immunohistochemistry for growth hormone or prolactin.
Acidophils measure about 10 to 20 micrometres in diameter and are round, oval or polygonal, with a round, often eccentric nucleus and a prominent nucleolus. Somatotrophs are usually smaller and more regular, with dense, evenly sized granules about 300 to 450 nanometres across. Lactotrophs are larger and more irregular, with granules about 500 to 700 nanometres in diameter that enlarge during pregnancy and lactation, producing the so-called pregnancy cells. Electron microscopy shows abundant rough endoplasmic reticulum, a prominent Golgi apparatus, numerous mitochondria and scattered lysosomes, with granules moving along microtubules toward the plasma membrane. These features reflect active peptide synthesis, packaging and release.
In the adult anterior pituitary, somatotrophs make up about 40 to 50 per cent of hormone-producing cells and lactotrophs about 10 to 25 per cent, with higher proportions in women and values above 30 per cent in late pregnancy. Somatotrophs are relatively more numerous in childhood, and both populations decline with age while lactotrophs become proportionally more prominent. Acidophils are embedded with folliculostellate cells, endothelial cells and extracellular matrix. Folliculostellate cells communicate through gap junctions, modulate hormone release by paracrine signals and participate in local immune responses.
The acidophil compartment is plastic. Pregnancy, lactation, oestrogen treatment, chronic stress and renal failure can produce lactotroph hyperplasia and hypertrophy, while starvation, hypoglycaemia and exercise cause somatotroph degranulation and a shift from acidophilic to chromophobic appearance. Chronic dopaminergic stimulation shrinks lactotrophs and reduces granule number, whereas dopamine receptor antagonists produce the opposite change. These adaptations are central to the pituitary response to endocrine demand and explain why histological interpretation must always be correlated with clinical and biochemical data.
Somatotrophs synthesize and secrete growth hormone, a single-chain polypeptide of 191 amino acids with a molecular mass of about 22 kilodaltons. Growth hormone is released in pulses, with increased frequency and amplitude during slow-wave sleep, exercise, hypoglycaemia, fasting and high-protein meals, and suppression by obesity, hyperglycaemia and elevated free fatty acids. Growth hormone-releasing hormone from the arcuate nucleus stimulates release, somatostatin from the periventricular nucleus inhibits it, and gastric ghrelin enhances it through hypothalamic and pituitary pathways. Growth hormone acts directly on hepatocytes, adipocytes, myocytes and chondrocytes and indirectly by stimulating hepatic insulin-like growth factor 1, which mediates linear growth. Its receptor belongs to the cytokine receptor family and signals through JAK2 and STAT5 to activate gene transcription, promoting protein synthesis, growth plate proliferation, lipolysis and insulin resistance.
Lactotrophs synthesize and secrete prolactin, a 198-amino-acid peptide of about 23 kilodaltons. Prolactin is expressed in the pituitary, decidua, breast, immune cells and prostate, but most circulating hormone comes from the pituitary. Its secretion is tonically inhibited by tuberoinfundibular dopaminergic neurons acting through D2 receptors on lactotrophs, whereas suckling, oestrogen, thyrotropin-releasing hormone, stress and sleep stimulate release. Prolactin drives alveolar development of the breast in pregnancy, initiates and maintains lactation after delivery, and suppresses hypothalamic gonadotropin-releasing hormone, producing lactational amenorrhoea and reduced fertility. It also contributes to osmoregulation, immune cell proliferation and angiogenesis, and in fish its principal role is water and ion balance.
Growth hormone and prolactin belong to the growth hormone-prolactin gene family, share partial structural homology and depend on the POU1F1 lineage during development. Growth hormone secretion is restrained by insulin-like growth factor 1 negative feedback and permitted by thyroid hormone, cortisol and sex steroids. Prolactin secretion is highly sensitive to dopaminergic tone, so any fall in hypothalamic dopamine or blockade of pituitary D2 receptors raises prolactin. Secretory rhythms differ between the sexes: women have higher growth hormone pulse amplitude and baseline, and higher baseline prolactin, reflecting direct effects of oestrogen on the anterior pituitary.
Acidophil secretion is tightly coupled to metabolic state. Growth hormone rises during fasting, promoting lipolysis and hepatic glucose output, and falls after a meal so that nutrients are directed toward synthesis and storage. Prolactin rises in the second half of sleep and peaks ten to thirty minutes after suckling. Growth hormone excess causes insulin resistance and impaired glucose tolerance, while chronic deficiency reduces muscle mass, bone density and alters lipid profile. Sustained hyperprolactinaemia suppresses the gonadal axis and causes amenorrhoea, galactorrhoea, reduced libido and bone loss. Granule stores and release rates determine circulating hormone levels, and granule density on immunohistochemistry does not directly equal secretory activity.
The anterior pituitary is supplied mainly by the superior hypophyseal arteries, which arise from the cavernous segment of the internal carotid artery and form a primary capillary plexus in the median eminence and proximal stalk. Blood from this plexus drains into long portal veins that descend along the stalk and form a secondary capillary plexus around acidophils. This portal system delivers hypothalamic releasing and inhibiting hormones at high concentration directly to the anterior pituitary and is the anatomical basis of neuroendocrine control. The inferior hypophyseal artery, a branch of the meningohypophyseal trunk of the internal carotid, supplies the posterior pituitary and stalk and contributes a smaller share to the lower anterior lobe.
Venous blood drains through the perihypophyseal venous plexus into the cavernous and intercavernous sinuses and then through the inferior and superior petrosal sinuses to the internal jugular vein. Because the pituitary lies in the sella turcica between the cavernous sinuses, a large adenoma can compress the oculomotor, trochlear and abducens nerves and the ophthalmic division of the trigeminal nerve, causing ophthalmoplegia and facial sensory loss. Suprasellar extension compresses the optic chiasm and produces bitemporal hemianopia. The transsphenoidal approach exploits the corridor between the sphenoid sinus and the sellar floor and avoids retraction of the frontal lobe and optic chiasm.
Anterior pituitary endocrine cells receive no direct synaptic input from hypothalamic neurons, and they are controlled chemically through portal hormones, the classic example of neuroendocrine control without synapses. Postganglionic sympathetic fibres from the superior cervical ganglion accompany the vessels, regulate vascular tone and blood flow and may influence folliculostellate cells, while parasympathetic fibres from the pterygopalatine ganglion have uncertain roles. The median eminence and posterior pituitary lack a complete blood-brain barrier, allowing exchange between hypothalamic hormones and circulating peptides, whereas the pars distalis has fenestrated endothelium that permits macromolecular hormone transfer into sinusoidal blood.
The local vascular arrangement has functional consequences. Fenestrated endothelial cells, discontinuous basement membrane and a thin layer of connective tissue allow hormones to reach the circulation within seconds. Folliculostellate cells extend processes around cell cords and form a paracrine network that modulates growth hormone and prolactin release. Capillary density and flow direction differ across the pars distalis and may contribute to secretory rhythms. Compression of the stalk or interruption of portal flow prevents hypothalamic hormones from reaching the anterior lobe and causes hypopituitarism, as seen in pituitary stalk interruption syndrome, craniopharyngioma and suprasellar tumours.
The adenohypophysis arises from Rathke's pouch, an ectodermal invagination of the stomodeum that forms around the fourth week of gestation. The anterior wall of the pouch proliferates and becomes the pars distalis, the posterior wall forms the pars intermedia and the upper wall forms the pars tuberalis. The neurohypophysis arises from the infundibular process of the diencephalic floor, so the two parts of the pituitary are adjacent but have different embryonic origins. Remnants of Rathke's pouch that fail to regress can form Rathke cleft cysts, lined by ciliated columnar epithelium and often containing mucoid material.
Anterior pituitary cell differentiation depends on a cascade of transcription factors. POU1F1 is expressed early and commits progenitors to the somatotroph, lactotroph and thyrotroph fates, while PROP1 acts upstream and maintains the POU1F1 lineage. Inactivating mutations in PROP1 or POU1F1 cause combined pituitary hormone deficiency, with growth hormone, prolactin, thyroid-stimulating hormone and gonadotropins affected to different degrees, with growth hormone deficiency usually appears first. HESX1, LHX3, LHX4 and SOX3 participate in pituitary placode formation and morphogenesis, and their mutations can be associated with septo-optic dysplasia, stalk interruption and ectopic posterior pituitary.
Growth hormone and prolactin immunoreactive cells can be detected in the human fetal pituitary during the first trimester. Somatotrophs appear at about eight to ten weeks and lactotrophs at about twelve to fourteen weeks, after which both populations expand rapidly. Fetal growth hormone secretion peaks at about twenty to twenty-four weeks and contributes to fetal growth and metabolism, while prolactin rises in late gestation under maternal oestrogen influence in preparation for lactation. After birth, somatotrophs continue to proliferate and lactotrophs increase after puberty under oestrogen influence.
The acidophil lineage retains considerable plasticity. Lineage-tracing studies show that somatotrophs and lactotrophs can transdifferentiate under physiological demand, for example when some somatotrophs become lactotrophs during pregnancy and revert after weaning. The existence, location and markers of adult pituitary stem cells remain debated, but the gland does show cell proliferation and hypertrophy after pregnancy, adrenalectomy and target gland ablation. Changes in acidophil number may therefore reflect proliferation, transdifferentiation, or changes in cell volume, and the relative contribution varies with model and species.
Somatotroph adenomas account for about 10 to 15 per cent of pituitary adenomas and cause acromegaly or gigantism. Before epiphyseal closure, excess growth hormone produces gigantism with excessive height, enlarged hands and feet and delayed sexual development, and after closure it causes acromegaly with broad hands and feet, coarse facial features, frontal bossing, macroglossia, thickened skin and hyperhidrosis. Patients often develop hypertension, diabetes, cardiomyopathy, sleep apnoea, arthropathy and colonic polyps, and cardiovascular complications are the main cause of death. Diagnosis rests on elevated random growth hormone, elevated insulin-like growth factor 1 and failure to suppress growth hormone during an oral glucose tolerance test. Transsphenoidal surgery is first-line treatment, with somatostatin analogues, pegvisomant or radiotherapy for persistent disease.
Prolactinomas are the most common functional pituitary adenomas, accounting for about 30 to 40 per cent of all pituitary adenomas. Women usually present with amenorrhoea, galactorrhoea, infertility and reduced libido, whereas men present with reduced libido, erectile dysfunction, gynaecomastia and infertility, so men are often diagnosed when the tumour is already large. Macroadenomas can compress the optic chiasm and cavernous sinus, causing visual field loss, ophthalmoplegia and headache. Diagnosis requires exclusion of drug-induced hyperprolactinaemia, primary hypothyroidism, renal failure, pregnancy and macroprolactinaemia. Dopamine agonists such as bromocriptine and cabergoline are first-line therapy and shrink most prolactinomas, with surgery reserved for resistance, intolerance or compression.
Acidophil stem cell adenomas are rare, accounting for less than 1 per cent of pituitary adenomas, and are composed of cells expressing both growth hormone and prolactin. They often cause acromegaly together with hyperprolactinaemia, are invasive into the cavernous sinus and suprasellar region, and have a high recurrence rate. Responses to dopamine agonists and somatostatin analogues are variable. Pathologically they show pleomorphism, fibrosis and acidophilic granules, with immunohistochemical positivity for growth hormone, prolactin and POU1F1, and must be distinguished from somatotroph and lactotroph adenomas.
Pituitary apoplexy is sudden haemorrhage or infarction within a pituitary adenoma, causing acute expansion and raised intrasellar pressure. Patients develop severe headache, nausea and vomiting, visual loss, ophthalmoplegia, altered consciousness and acute adrenal insufficiency, which can be fatal. Somatotroph and lactotroph adenomas, particularly acidophil tumours, are common underlying lesions. Management includes urgent intravenous glucocorticoids, correction of electrolyte disturbance and emergency transsphenoidal decompression when vision is threatened. Sheehan syndrome is ischemic necrosis of the anterior pituitary after postpartum haemorrhage and hypotension, with failure of lactation, amenorrhoea, hypothyroidism and adrenal insufficiency, and growth hormone and prolactin deficiency usually occur early.
Lymphocytic hypophysitis occurs mainly in late pregnancy and the postpartum period and presents with headache, visual disturbance, pituitary enlargement and anterior pituitary failure, sometimes with diabetes insipidus and hyperprolactinaemia. Imaging shows diffuse pituitary enlargement and stalk thickening, and the diagnosis is confirmed by pathology or clinical follow-up. Cranial radiotherapy can cause delayed growth hormone, prolactin and thyroid-stimulating hormone deficiency years later, and growth hormone deficiency is the most common deficit after childhood irradiation. Drugs such as antipsychotics, metoclopramide and some antidepressants raise prolactin by blocking D2 receptors, while oestrogen and pregnancy cause lactotroph hyperplasia and pituitary enlargement.
Imaging is central to the evaluation of acidophil lesions. Dynamic contrast-enhanced magnetic resonance imaging shows microadenomas as hypoenhancing foci, with microadenomas are smaller than 10 millimetres, whereas macroadenomas exceed 10 millimetres and may invade the cavernous sinus, suprasellar cistern and sphenoid sinus. Computed tomography shows sellar enlargement, thinning of the sellar floor and calcification. Laboratory testing includes growth hormone, insulin-like growth factor 1, prolactin, thyroid-stimulating hormone, adrenocorticotropic hormone and gonadotropins, with inferior petrosal sinus sampling when the source of adrenocorticotropic hormone is uncertain. Treatment choice among surgery, medical therapy and radiotherapy depends on tumour size, hormone type, visual status, age and fertility plans.
The adenohypophysis is present in all vertebrates, but the composition, proportion and hormonal roles of acidophils vary across lineages. In teleost fish prolactin is a major osmoregulatory hormone, with lactotroph-like cells controlling water and ion transport across gills and kidney, while growth hormone participates in growth, metabolism and seawater adaptation. Fish anterior pituitary cells are classified by tinctorial properties, but individual cells can express more than one hormone and the acidophil-basophil boundary is less distinct than in mammals.
In amphibians prolactin contributes to water balance, skin permeability and metamorphic timing, and growth hormone promotes growth. In birds prolactin supports crop milk production and parental behaviour, growth hormone regulates growth and metabolism, and acidophils increase during the breeding season. Mammals show the most distinct acidophil differentiation, with growth hormone and prolactin produced by separate cell populations, and placental lactogen expressed by syncytiotrophoblast, structurally related to pituitary prolactin but functionally oriented toward maternal-fetal metabolism and mammary preparation.
Pituitary morphology differs widely. The fish pituitary is flattened and lies ventral to the diencephalon, while amphibian and reptilian pituitaries remain connected to the infundibulum, while bird and mammal pituitaries lie within the sella turcica with an expanded anterior lobe. Pituitary size and sellar anatomy differ among horses, cattle, dogs and cats, and acidophil proportions vary accordingly, and primate anterior pituitaries resemble the human gland. For cross-coding, the acidophil cell corresponds to FMA:83629 and Wikidata Q4674118, the anterior pituitary to the UBERON adenohypophysis entry, and MeSH indexes anterior pituitary cells separately from somatotrophs and lactotrophs.
Late nineteenth-century histologists used aniline dyes to divide anterior pituitary cells into acidophilic, basophilic and chromophobic types. Benda and Erdheim described pituitary adenoma morphology in the early twentieth century and linked acidophil adenomas to acromegaly, establishing the clinical pathology of the acidophil-growth hormone axis before the hormone itself was known. At that time cell function could only be inferred from staining reactions and clinical behaviour.
Growth hormone was identified in bovine anterior pituitary extracts in the 1920s and shown to promote growth in rats, and prolactin was recognised in the 1930s as a hormone separate from growth hormone, assayed by its effect on pigeon crop epithelium. Growth hormone was crystallised and its amino acid composition determined in the 1950s, and the radioimmunoassay developed in the 1960s made it possible to measure growth hormone and prolactin in blood, advancing the diagnosis of acromegaly and hyperprolactinaemia.
Immunohistochemistry in the 1970s moved pituitary cell classification from tinctorial morphology to hormone identity, allowing somatotrophs, lactotrophs, corticotrophs, thyrotrophs and gonadotrophs to be distinguished in the same section. Growth hormone and prolactin genes were cloned in the 1980s, their receptors and signalling pathways were defined, and the growth hormone receptor antagonist pegvisomant entered clinical use for acromegaly in the 1990s. The 2017 World Health Organization classification of pituitary tumours introduced transcription factor lineages, dividing adenomas into POU1F1, TPIT and SF1 lineages, with acidophil tumours falling mainly into the POU1F1 group.
Terminologically, acidophils are also called acidophil cells, acidophilic cells or pituitary acidophils, and must be distinguished from eosinophils, which are white blood cells rather than pituitary cells. Terminologia Anatomica and the Foundational Model of Anatomy index the concept among pars distalis cells, and the Chinese standard name is 嗜酸性细胞, and clinical pathology reports sometimes shorten this to acidophil adenoma cells. These naming differences are a practical trap when searching the literature and comparing pathology reports.
Single-cell RNA sequencing has revealed transcriptional heterogeneity beyond the classical five pituitary cell types, with some cells co-expressing growth hormone and prolactin or expressing genes usually assigned to other lineages. These findings challenge the simplified model of one cell-one hormone and suggest that the cellular origin of pituitary adenomas may be more complex than previously assumed. The proportion of bihormonal cells in the normal gland, whether they represent an intermediate differentiation state, and their role in tumorigenesis remain active questions.
Whether a true adult pituitary stem cell exists is disputed. Some studies report SOX2-positive, nestin-positive progenitors that form pituitary-like organoids in vitro, whereas other lineage-tracing studies argue that adult pituitary turnover depends mainly on proliferation and transdifferentiation of existing cells rather than multipotent stem cells. The source of lactotroph expansion in pregnancy, whether proliferation, transdifferentiation or both, differs among models, and the answer affects understanding of postpartum pituitary recovery and hypopituitarism.
The clonal origin of pituitary adenomas is also debated. Most studies support a monoclonal origin from a single mutated precursor, with GNAS activating mutations in about 40 per cent of somatotroph adenomas, MEN1 and AIP mutations in some familial and young-onset cases, and CDKN1B mutations in multiple endocrine neoplasia. However, somatic mutations and abnormal cell nests in normal pituitary suggest that a field effect may contribute, particularly in multiple and familial adenomas. Why the same mutation produces different hormone phenotypes in different individuals remains incompletely explained.
Clinical controversies centre on the diagnosis and management of hyperprolactinaemia. Macroprolactin and the hook effect can cause falsely high or falsely low prolactin, requiring polyethylene glycol precipitation and dilution. Whether to stop, switch or add a dopamine agonist in antipsychotic-induced hyperprolactinaemia requires balancing the risk of psychiatric relapse. Long-term dopamine agonist therapy may cause tumour fibrosis and complicate later surgery, but follow-up studies disagree, and recurrence after withdrawal is common, so withdrawal criteria and surveillance schedules remain unsettled. Biochemical remission criteria for somatotroph adenomas, radiotherapy dose and timing, and the long-term cardiovascular benefit of newer somatostatin analogues are still under study.